Asana’s mission is to develop novel and clinically differentiated products that address unmet clinical needs and provide new treatment options to physicians and patients.
Asana BioSciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel targeted therapies in inflammation/immunology and oncology.
Asana’s proprietary portfolio comprises multiple drug candidates, both small molecules and biologics. Our lead asset, ASN002, is an oral dual JAK/SYK inhibitor in Phase 2b clinical development for patients with moderate to severe atopic dermatitis and has broad development potential in other immunological diseases. Our oncology leads are targeted therapies in early clinical development for patients with advanced or metastatic cancers, including melanoma, non-small cell lung cancer, colorectal cancer and other solid tumors.
Asana BioSciences was founded in 2014 and is based near Princeton, NJ.